NRF1 activation suppresses EMT and tumor progression in lung adenocarcinoma by boosting mitochondrial biogenesis
Background
Lung cancer remains the leading cause of cancer-related mortality, with challenges like drug resistance and tumor heterogeneity hindering effective therapies. Epithelial-mesenchymal transition (EMT) is a critical process driving cancer initiation, metastasis, and therapeutic resistance. Nuclear respiratory factor 1 (NRF1), a transcription factor, is known for its roles in mitochondrial biogenesis and apoptosis, both crucial for cellular health and cancer progression. Understanding NRF1's precise involvement in lung cancer could reveal novel therapeutic targets to overcome current treatment limitations.
Study Design
Researchers investigated NRF1's role in lung adenocarcinoma using A549 lung adenocarcinoma cells and SCID mice. In vitro, NRF1 was either overexpressed using pcDNA-NRF1 or silenced via shRNA-NRF1. Key markers for EMT (E-cadherin, N-cadherin, vimentin), mitochondrial biogenesis (T-fam), and apoptosis (caspase-3, caspase-9) were assessed using western blotting. Functional assays measured cell migration and apoptosis. For in vivo validation, SCID mice were implanted with NRF1-modified tumors, with tumor progression and marker expression evaluated. Statistical significance was set at p<0.05.
Results
NRF1 overexpression significantly inhibited epithelial-mesenchymal transition (EMT). Specifically, it increased E-cadherin levels while reducing N-cadherin and vimentin expression. This overexpression also suppressed cell migration and enhanced mitochondrial biogenesis, evidenced by elevated T-fam levels. Apoptosis was also promoted, indicated by increased activity of caspase-3 and caspase-9. Conversely, NRF1 silencing led to the opposite effects, promoting EMT, reducing mitochondrial biogenesis, and decreasing apoptosis. In vivo, NRF1-overexpressing tumors in SCID mice mirrored these findings: they exhibited higher levels of E-cadherin, T-fam, and caspase-3, confirming NRF1's role in EMT suppression and the enhancement of mitochondrial and apoptotic pathways. The study concluded that NRF1 activates the AMPK/SIRT1/PGC-1α/TFAM axis to mediate these effects.
NRF1 overexpression increased E-cadherin while reducing N-cadherin and vimentin, inhibiting EMT and suppressing cell migration, while enhancing mitochondrial biogenesis and apoptosis.
Key Findings
- NRF1 overexpression increased E-cadherin while reducing N-cadherin and vimentin, indicating EMT inhibition.
- NRF1 overexpression suppressed cell migration and enhanced mitochondrial biogenesis, with elevated T-fam levels.
- NRF1 overexpression promoted apoptosis, evidenced by increased caspase-3 and caspase-9 activity.
- In vivo, NRF1-overexpressing tumors in SCID mice showed higher E-cadherin, T-fam, and caspase-3 levels.
- NRF1 mediates its effects by activating the
AMPK/SIRT1/PGC-1α/TFAMaxis.
Why It Matters
This study identifies NRF1 as a critical suppressor of EMT and a promoter of mitochondrial health and apoptosis in lung adenocarcinoma. For those interested in cancer research and potential therapeutic strategies, this suggests that targeting NRF1 could offer a novel approach to inhibit tumor progression and potentially overcome resistance to conventional therapies. Activating NRF1 pathways could be explored as a strategy to combat lung cancer metastasis and improve treatment efficacy. While this is preclinical data, it lays the groundwork for future drug development focusing on NRF1 modulators. Further research is needed to translate these findings into human-applicable protocols or compounds, but the mechanistic insight is significant for understanding cancer biology.
nrf1
lung-adenocarcinoma
emt
mitochondrial-biogenesis
apoptosis
ampk